Market Place
Sourcing Support
Kailera, Hengrui To Advance Oral Obesity Drug Into 2 New Trials
10 Feb 2026 //
FIERCE BIOTECH
Kailera Therapeutics Starts Global Phase 3 Trial For Ribupatide
12 Jan 2026 //
GLOBENEWSWIRE
Kailera Therapeutics Names Doug Pagán as CFO
05 Jan 2026 //
GLOBENEWSWIRE
Kailera Therapeutics To Present At J.P. Morgan Healthcare
23 Dec 2025 //
GLOBENEWSWIRE
Kailera Therapeutics To Join November Investor Conferences
05 Nov 2025 //
GLOBENEWSWIRE
Hengrui & Kailera Share Ph3 China Data on Dual GLP-1/GIP Agonist
04 Nov 2025 //
GLOBENEWSWIRE
Hengrui Pharma, Kailera Therapeutics To Present Phase 3 HRS9531
21 Oct 2025 //
GLOBENEWSWIRE
Kailera Therapeutics Secures $600M To Advance Obesity Therapies
14 Oct 2025 //
GLOBENEWSWIRE
Kailera Therapeutics to Present at Investor Conferences
27 Aug 2025 //
GLOBENEWSWIRE
Hengrui, Kailera Report Positive Ph 3 Obesity Results in China
15 Jul 2025 //
GLOBENEWSWIRE
Jiangsu Hengrui and Kailera present data at ADA 85th Sessions
16 Jun 2025 //
GLOBENEWSWIRE
Kailera Therapeutics Adds Adam Koppel, Christopher Hite to Board
05 Jun 2025 //
GLOBENEWSWIRE
Kailera Therapeutics Appoints Jamie as Chief Commercial Officer
27 Jan 2025 //
GLOBENEWSWIRE
Hengrui & Kailera Report Positive Phase 2 Obesity Data For HRS9531
13 Jan 2025 //
GLOBENEWSWIRE
Kailera Therapeutics Appoints Laurie as Chief Financial Officer
08 Jan 2025 //
GLOBENEWSWIRE
Kailera Therapeutics to Present at 43rd J.P. Morgan Conference
06 Jan 2025 //
GLOBENEWSWIRE
Kailera Therapeutics Appoints Scott M. as Chief Legal Officer
12 Nov 2024 //
GLOBENEWSWIRE
Kailera Launches with $400M Series A for Obesity Therapies
01 Oct 2024 //
GLOBENEWSWIRE
Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.